Cite
HARVARD Citation
Wallace, D. et al. (2017). Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. Annals of the rheumatic diseases. 76 (3), pp. 534-542. [Online].